Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.44 |
| ▸ | CES1 | P23141 | 2/20 | 0.44 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | FAP | Q12884 | 1/20 | 0.31 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.31 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.31 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18249655 | 0.85 | CES2 (0.41) | CES2CES1TRPM8DPP4FAP | |
| SCHEMBL18249569 | 0.83 | CES2 (0.31) | CES2CES1 | |
| SCHEMBL18249644 | 0.82 | CES2 (0.44) | CES2CES1DPP4DPP8DPP9 | |
| SCHEMBL18249625 | 0.80 | DPP4 (0.42) | CES2CES1DPP4 | |
| SCHEMBL18249563 | 0.80 | CES2 (0.41) | CES2CES1TRPM8DPP4DPP9 | |
| SCHEMBL18249571 | 0.80 | CA1 (0.32) | CES2CES1 | |
| SCHEMBL20164102 | 0.79 | CES2 (0.44) | CES2CES1DPP4DPP7 | |
| SCHEMBL18249584 | 0.78 | CES2 (0.40) | CES2CES1TRPM8DPP4DPP8 | |
| SCHEMBL18250064 | 0.78 | CES2 (0.43) | CES2CES1DPP4DPP7PDE2A | |
| SCHEMBL18249634 | 0.75 | CES2 (0.32) | CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3297987-B1 | NOVEL AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATHECOLAMINERGIC NEUROTRANSMISSION | INTEGRATIVE RES LABORATORIES SWEDEN AB (SE) | 2019-05-15 | — | — | EP | disclosed |
| US-10287247-B2 | Azetidine derivatives useful as modulators of cortical cathecolaminergic neurotransmission | INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB (SE) | 2019-05-14 | — | — | US | disclosed |
| US-20190031606-A1 | NOVEL AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATHECOLAMINERGIC NEUROTRANSMISSION | INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB (SE) | 2019-01-31 | — | — | US | disclosed |
| US-10087142-B2 | Azetidine derivatives useful as modulators of cortical cathecolaminergic neurotransmission | INTEGRATIVE RESEARCH LABORATORIES (SE) | 2018-10-02 | — | — | US | disclosed |
| US-20180141903-A1 | NOVEL AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATHECOLAMINERGIC NEUROTRANSMISSION | INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB (SE) | 2018-05-24 | — | — | US | disclosed |
| EP-3297987-A1 | NOVEL AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATHECOLAMINERGIC NEUROTRANSMISSION | Integrative Research Laboratories Sweden AB (SE) | 2018-03-28 | — | — | EP | disclosed |
| WO-2016185032-A1 | NOVEL AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATHECOLAMINERGIC NEUROTRANSMISSION | INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB (SE) | 2016-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141903-A1 | NOVEL AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATHECOLAMINERGIC NEUROTRANSMISSION | SLC18A2, SLC18A1, SLC18A3 | CES2 233/4885CES1 2329/4885TRPM8 2283/4885 |
| US-10287247-B2 | Azetidine derivatives useful as modulators of cortical cathecolaminergic neurotransmission | SLC18A2, SLC6A2, SLC18A3 | CES2 166/4885CES1 2533/4885TRPM8 2308/4885 |
| US-10087142-B2 | Azetidine derivatives useful as modulators of cortical cathecolaminergic neurotransmission | SLC18A2, SLC6A2, SLC18A1 | CES2 161/4885CES1 2089/4885TRPM8 2746/4885 |
| US-20190031606-A1 | NOVEL AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATHECOLAMINERGIC NEUROTRANSMISSION | SLC18A2, SLC6A2, SLC18A3 | CES2 254/4885CES1 2957/4885TRPM8 1700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.